Listed

Callan JMB Inc.: Form 10-Q for the period ended Jun 30, 2026

Filed with the SEC on Aug 14, 2026 and accepted by EDGAR at Aug 14, 2026, 16:06 ET.

Share

Management's discussion and analysis

As filed, 15,108 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis is intended as a review of significant factors affecting our financial condition and results of operations for the periods indicated. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our” refer to Callan JMB Inc.

Forward-Looking Statements

The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in our filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.

Overview

Callan JMB is a vertically integrated logistics and fulfillment company which provides thermal management logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and specialized cold chain logistics knowhow. We provide a system that utilizes advanced predictive technology to revolutionize the supply chain by guaranteeing the safety, effectiveness, and potency of every product handled to ensure product integrity, and to provide immediate response in time-sensitive industries while ensuring environmental responsibility.

Strategy

Our strategy involves leveraging our core competitive strengths to develop and maintain ongoing relationships with a diversified group of customers while continuing to grow our service lines, ensuring that we can meet our customers’ changing needs. We strive to be recognized as the premier provider of logistics and fulfillment of a broad range of value-added services based upon the breadth of those services, quality, responsiveness, customer service, information technologies, safety, and cost effectiveness.

We view our solutions as disruptive to the “older technologies” of dry ice and liquid nitrogen, in that our solutions are comprehensive and combine our competencies in configurations that are customized to our client’s requirements. We provide comprehensive, reliable, economic alternatives to all existing logistics solutions and services utilized for frozen shipping in the life sciences industry (e.g., personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). As part of our services, we provide the ability to monitor, record and archive crucial information for each shipment that can be used for scientific and regulatory purposes.

Seasonality

Based on our industry and our historic trends, we expect our operations to vary seasonally. Typically, revenue will be highest in the third and fourth calendar quarters and lowest in the first and second calendar quarters. These seasonal variations result in fluctuations in waste volumes due to weather conditions and general economic activity. We also expect that our operating expenses may be higher during the winter months due to periodic adverse weather conditions that can slow the collection of waste, resulting in higher labor and operational costs.

Results of Operations

Three and Six Months Ended June 30, 2026, Compared to the Three and Six Months Ended June 30, 2025

The following table provides certain selected financial information for the periods presented:

(Unaudited)

Three months ended June 30, 2026 2025 Change Change %
Revenue $1,376,326 $1,666,309 $(289,983) -17%
Cost of Revenue 618,380 1,022,439 (404,059) -40%
Gross Profit $757,946 $643,870 $114,076 18%
Selling, General and administrative expenses 2,104,592 2,050,410 54,182 3%
Loss from operations $(1,346,646) $(1,406,540) $59,894 -4%
Other income (expense) 119,557 2,042 117,515 5755%
Loss before income taxes $(1,227,089) $(1,404,498) $177,409 -13%
Provision for income taxes 4,834 (3,102) 7,936 -256%
Net loss $(1,231,923) $(1,401,396) $169,473 -12%

(Unaudited)

Six months ended June 30, 2026 2025 Change Change %
Revenue $2,482,468 $3,115,687 $(633,219) -20%
Cost of Revenue 1,297,288 1,858,724 (561,436) -30%
Gross Profit $1,185,180 $1,256,963 $(71,783) -6%
Selling, General and administrative expenses 4,233,015 3,901,878 331,137 8%
Loss from operations $(3,047,835) $(2,644,915) $(402,920) 15%
Other income (expense) (1,394,002) 4,188 (1,398,190) 33386%
Loss before income taxes $(4,441,837) $(2,640,727) $(1,801,110) 68%
Provision for income taxes 5,140 1,259 3,881 308%
Net loss $(4,446,977) $(2,641,986) $(1,804,991) 68%

Revenue

Revenue for the three and six months ended June 30, 2026, was $1,376,326 and $2,482,468 respectively as compared to $1,666,309 and $3,115,687 for the three and six months ended June 30, 2025, a decrease of $289,983 and $633,219 respectively. This decrease was due to the decrease in demand for our emergency preparedness services by certain states and local governments.

Cost of revenue

Cost of revenue for the three and six months ended June 30, 2026, was $618,380 and $1,297,288, respectively, as compared to $1,022,439 and $1,858,724 for the three and six months ended June 30, 2025, respectively. The majority of the decrease in the cost of revenue is driven by the decrease in revenue for both comparative periods. The decrease in the comparative three-month period is also attributable to a $44,639 decrease in shippers and components costs and a $21,608 decrease in direct labor costs, partially offset by a $20,208 increase in repairs and maintenance expense. The decrease in the comparative six-month period is also attributable to a $244,296 decrease in direct labor costs, a $116,679 decrease in freight forwarding expense, a $107,215 decrease in shippers and components costs, and a $93,043 decrease in medical supplies expense.

Operating Expenses

Selling, General and Administrative Expenses

Our selling, general and administrative costs include personnel costs, consulting and professional fees, and other overhead expenses. Selling, general and administrative expenses for the three and six months ended June 30, 2026, were $2,104,592 and $4,233,015 respectively compared to $2,050,410 and $3,901,878 respectively for the three and six months ended June 30, 2025, an increase of $54,182 and $331,137 respectively. The increase in the comparative three-month period was primarily attributable to a $232,118 increase in legal expenses and a $66,711 increase in salaries and benefits, partially offset by a $123,366 decrease in accounting fees, a $36,013 decrease in bad debt expense, and a $34,038 decrease in marketing strategy expenses. The increase in the comparative six-month period was primarily attributable to a $274,411 increase in legal expenses, a $153,038 increase in accounting fees, a $147,260 increase in salaries and benefits, a $95,335 increase in rent expense, and a $71,928 increase in other operating costs, partially offset by a $187,944 decrease in marketing strategy expenses and a $91,201 decrease in other professional fees.

Other income (expense)

Other income (expense) for the three months ended June 30, 2026, was $119,557 and $2,042 for the three months ended June 30, 2025, resulting in an increase in other income of $117,515. Other income (expense) for the six months ended June 30, 2026, was $(1,394,002) and $4,188 for the six months ended June 30, 2025, resulting in an increase in other expense of $1,398,190. The key driver for the decrease relates to changes in the fair value of the ELOC facility as well as related expenses. Refer to the discussion under Note 6 “Equity” for further information on the ELOC Facility. The change in the fair value of the Derivative Liability during the three and six months ended June 30, 2026, was a decrease of $120,841 and an increase of $217,388, respectively. The Company also recognized other transaction expenses arising from the ELOC Facility of $1,177,223 during the six months ended June 30, 2026. Further, during the six months ended June 30, 2026, the Company finalized a settlement with its former executive related to previously existing claims, which resulted in a payment of $150,000, which was offset by an insurance recovery from the Company’s directors and officers insurance policy of $150,000.

Liquidity and Capital Resources

Our principal liquidity requirements are for working capital to fund our operations and growth. To date, we have funded our liquidity requirements through a combination of cash on hand, cash flows from operations, and funding from various sources, including from the CEO. As of June 30, 2026, we had $860,273 cash and cash equivalents.

As of June 30, 2026, the Company had an accumulated deficit of $(14,706,991) and negative cash flow from operating activities of $(2,075,943) for the six months ended June 30, 2026. In addition, the Company incurred a net loss of $(4,446,977) for the six months ended June 30, 2026 and had cash and cash equivalents of $860,273 as of June 30, 2026. The Company has recurring losses, has not yet generated sufficient cash flows from operations to fund its activities, and expects to continue incurring operating losses and using cash in support of its business plan. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. Accordingly, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.

Since inception, the Company has funded its operations through operating cash flows, the ELOC Facility, and capital contributions or other funding from Mr. Williams. Management will continue to evaluate additional sources of capital, including equity and debt financings. However, the availability and terms of future financing are subject to market conditions, investor demand, and the Company’s operating performance, and there can be no assurance that additional capital will be available when needed or on acceptable terms

On April 7, 2026, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders’ equity for continued listing on The Nasdaq Capital Market. The Company submitted a compliance plan to Nasdaq and is working to regain compliance; however, there can be no assurance that the Company will regain compliance within any period granted by Nasdaq.

On June 29, 2026, the Company received an additional notice from Nasdaq indicating that it was not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. The Company has until December 28, 2026 to regain compliance with the minimum bid price requirement. The notices have no immediate effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol “CJMB.”

The Company is actively monitoring its compliance with Nasdaq’s continued listing requirements and evaluating alternatives to regain and maintain compliance. There can be no assurance that the Company will regain compliance with the applicable Nasdaq listing standards or otherwise maintain compliance with the continued listing requirements of The Nasdaq Capital Market.

(Unaudited)

For Six Months Ended June 30, 2026 2025 Change
Cash used in operating activities $(2,075,943) $(2,124,970) $49,027
Cash used in investing activities (69,481) (447,506) 378,025
Cash provided by financing activities 874,939 4,698,682 (3,823,743)
Increase (decrease) in cash and cash equivalents $(1,270,485) $2,126,206 $(3,396,691)

26

Cash provided by (used in) operating activities

For the six months ended June 30, 2026, cash used in operating activities was $(2,075,943) compared to cash used in operating activities of $(2,124,970) during the six months ended June 30, 2025, a decrease of $49,027. This decrease was primarily due to a decrease in accounts receivable of $82,091, in addition to the balance of recovering from credit losses for $37,750 with resulting net change in accounts receivable of $119,841.

Cash provided by (used in) investing activities

For the six months ended June 30, 2026, cash used in investing activities was $(69,481) compared to $(447,506) for the six months ended June 30, 2025, a decrease of $378,025. The decrease is a result of leasehold improvements made to the new corporate office during 2025.

Cash provided by (used in) financing activities

During the six months ended June 30, 2026, cash provided by financing activities was $874,939 compared to $4,698,682 during the six months ended June 30, 2025, a decrease of $(3,823,743). Our financing activities for the six months ended June 30, 2026 compared to June 30, 2025 included an increase in proceeds from the offering of ELOC shares of $1,000,000, which is offset by prior year proceeds raised from IPO and overallotment of $4,680,013.

Off-Balance Sheet Arrangements

We have no off-balance sheet financing arrangements.

Market risk

As filed, 180 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Under SEC rules and regulations, because we are considered to be a “smaller reporting company,” we are not required to provide the information required by this item in this report.

Controls and procedures

As filed, 2,649 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of June 30, 2026, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of June 30, 2026, our disclosure controls and procedures were not effective. Management identified a material weakness on the timeliness and consistency of execution of oversight reviews and governance impacting the performance of certain internal control activities, which affected the Company’s ability to consistently achieve its control objectives. During the year ended December 31, 2025, the Company continued to develop and refine its disclosure controls and other procedures designed to ensure that information required to be disclosed in reports filed with the SEC is recorded, processed, summarized, and reported within the time periods specified by SEC rules and forms. In response to the identified ineffectiveness of controls, management has worked on enhancing oversight and governance processes, improving documentation of accounting policies and procedures, and engaged experienced third-party advisors to support GAAP compliance and financial reporting. While progress was made during the year ended December 31, 2025 and has continued through the six months ended June 30, 2026, remediation of the material weakness will not be considered complete until the redesigned controls have operated effectively for a sustained period and have been validated through testing.

(b) Changes in Internal Controls Over Financial Reporting

There were no changes in our internal controls over financial reporting that occurred during the last fiscal quarter covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 173 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this Item.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2026-04-01 to 2026-06-30$1.4mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2026-01-01 to 2026-06-30$2.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2026-04-01 to 2026-06-30$618.4kus-gaap:CostOfRevenue
Cost of revenue6 months2026-01-01 to 2026-06-30$1.3mus-gaap:CostOfRevenue
Gross profit3 months2026-04-01 to 2026-06-30$757.9kus-gaap:GrossProfit
Gross profit6 months2026-01-01 to 2026-06-30$1.2mus-gaap:GrossProfit
Selling, general and administrative3 months2026-04-01 to 2026-06-30$2.1mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2026-01-01 to 2026-06-30$4.2mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2026-04-01 to 2026-06-30−$1.3mus-gaap:OperatingIncomeLoss
Operating income6 months2026-01-01 to 2026-06-30−$3.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2026-04-01 to 2026-06-30$2.4kus-gaap:InterestExpenseNonoperating
Interest expense6 months2026-01-01 to 2026-06-30$2.4kus-gaap:InterestExpenseNonoperating
Income tax3 months2026-04-01 to 2026-06-30$4.8kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2026-01-01 to 2026-06-30$5.1kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2026-04-01 to 2026-06-30−$1.2mus-gaap:NetIncomeLoss
Net income6 months2026-01-01 to 2026-06-30−$4.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2026-04-01 to 2026-06-30−$0.22us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2026-01-01 to 2026-06-30−$0.80us-gaap:EarningsPerShareDiluted
Basic EPS3 months2026-04-01 to 2026-06-30−$0.22us-gaap:EarningsPerShareBasic
Basic EPS6 months2026-01-01 to 2026-06-30−$0.80us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2026-04-01 to 2026-06-305,646,118 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2026-01-01 to 2026-06-305,551,248 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2026-01-01 to 2026-06-30−$2.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2026-01-01 to 2026-06-30$69.5kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2026-06-30$860.3kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2026-06-30$1.8mus-gaap:AssetsCurrent
Total assetsAt period end2026-06-30$4.5mus-gaap:Assets
Current liabilitiesAt period end2026-06-30$1.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2026-06-30$3.8mus-gaap:Liabilities
Shareholders' equityAt period end2026-06-30$681.9kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-26-038329. Last ingested by Listed: Nov 14, 2026, 21:10 ET. Listed shows no prices and gives no investment advice.